Pathophysiology roles for adenosine 2A receptor in obesity and related diseases

Cai, Yuli; Chen, Xiaolin; Yi, Bo; Li, Junfeng; Wen, Zhongyuan

doi:10.1111/obr.13490

Cited by 7 publications

(7 citation statements)

References 139 publications

(239 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Firstly, the inflammatory status may be critical to linking OA and NAFLD. For instance, the activation of adenosine 2A receptors (A2AR) is closely related to the downregulation of OA inflammation[ 30 ]. Similarly, A2AR also is involved in NAFLD.…”

Section: Discussionmentioning

confidence: 99%

Association of non-alcoholic fatty liver disease with self-reported osteoarthritis among the US adults

Lu,

Zhang,

et al. 2024

Arthritis Res Ther

View full text Add to dashboard Cite

Background The association between non-alcoholic fatty liver disease (NAFLD) and osteoarthritis (OA) has not been well elucidated. The aim of the present study was to investigate the association between NAFLD and OA in the US adults. Methods A cross-sectional study was performed on participants in the 2017–2018 National Health and Nutrition Examination Survey (NHANES) cycle. NAFLD was defined by the vibration-controlled transient elastography. The diagnosis of OA was based on self-reported data. Weighted multiple logistic regression models and stratified analyses were performed to explore the relationship and verify the stability of the conclusions. Sensitivity analysis using multiple imputation for missing data and propensity score matching (PSM) were performed. Results In total, 2622 participants [Male: 1260 (47.8%)] were included in this study with a mean age of 48.1 years old (95% CI, 46.6–49.6 years old), containing 317 (12.8%) OA patients and 1140 NAFLD patients (41.5%). A logistic regression indicated a significant association between NAFLD and OA without adjustment [odds ratio (OR) = 2.05; 95% CI, 1.52–2.78]. The association remained stable after adjustment for covariates (OR = 1.72; 95% CI, 1.26–2.34). Sensitivity analysis of missing data with multiple interpolation and PSM found similar results. A significant and consistent association of NAFLD with OA was still observed in each subgroup stratified by age and metabolic syndrome (MetS). Stratified by sex, obesity, and sensitivity c-reactive protein (hs-CRP) category, a statistically significant association was only shown in females, those without obesity, and those without hyper hs-CRP. The results illustrated that the relationship between NAFLD and OA was stable in all subgroups and had no interaction. Conclusions NAFLD was positively correlated with OA. Given the current pandemic of NAFLD and OA, clinicians should screen for NAFLD in arthritis patients and intervene early.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of non-alcoholic fatty liver disease with self-reported osteoarthritis among the US adults

Lu,

Zhang,

et al. 2024

Arthritis Res Ther

View full text Add to dashboard Cite

show abstract

“…There are only few studies describing a potential influence of adenosine on obesity. Hereby, the A2aR subtype seems to play the major role, which is abundantly expressed in adipose tissue [ 213 ]. The activation of this receptor protected mice from HFD-induced obesity by inducing the so-called “browning” of the white adipose tissue [ 214 ].…”

Section: Sympathetic Influence On Mild Chronic Inflammatory Diseasesmentioning

confidence: 99%

Role of the Sympathetic Nervous System in Mild Chronic Inflammatory Diseases: Focus on Osteoarthritis

Sohn¹,

Jenei-Lanzl²

2023

Neuroimmunomodulation

View full text Add to dashboard Cite

The sympathetic nervous system (SNS) is a major regulatory mediator connecting the brain and the immune system that influences accordingly inflammatory processes within the entire body. In the periphery, the SNS exerts its effects mainly via its neurotransmitters norepinephrine (NE) and epinephrine (E), which are released by peripheral nerve endings in lymphatic organs and other tissues. Depending on their concentration, NE and E bind to specific α- and β-adrenergic receptor subtypes and can cause both pro- and anti-inflammatory cellular responses. The co-transmitter neuropeptide Y, adenosine triphosphate, or its metabolite adenosine are also mediators of the SNS. Local pro-inflammatory processes due to injury or pathogens lead to an activation of the SNS, which in turn induces several immunoregulatory mechanisms with either pro- or anti-inflammatory effects depending on neurotransmitter concentration or pathological context. In chronic inflammatory diseases, the activity of the SNS is persistently elevated and can trigger detrimental pathological processes. Recently, the sympathetic contribution to mild chronic inflammatory diseases like osteoarthritis (OA) has attracted growing interest. OA is a whole-joint disease and is characterized by mild chronic inflammation in the joint. In this narrative article, we summarize the underlying mechanisms behind the sympathetic influence on inflammation during OA pathogenesis. In addition, OA comorbidities also accompanied by mild chronic inflammation, such as hypertension, obesity, diabetes, and depression, will be reviewed. Finally, the potential of SNS-based therapeutic options for the treatment of OA will be discussed.

show abstract

“…Moreover, ARs can influence glucose and lipid homeostasis. Therefore, agonists and antagonists of ARs have been explored as potential treatments for atherosclerosis, diabetes, obesity, and non-alcoholic fatty liver disease in preclinical and clinical studies [ 104 , 105 ].…”

Section: Ars In Cardiovascular and Metabolic Diseasesmentioning

confidence: 99%

Pharmacology of Adenosine Receptors: Recent Advancements

Vincenzi,

Pasquini,

Contri

et al. 2023

Biomolecules

View full text Add to dashboard Cite

Adenosine receptors (ARs) are widely acknowledged pharmacological targets yet are still underutilized in clinical practice. Their ubiquitous distribution in almost all cells and tissues of the body makes them, on the one hand, excellent candidates for numerous diseases, and on the other hand, intrinsically challenging to exploit selectively and in a site-specific manner. This review endeavors to comprehensively depict the substantial advancements witnessed in recent years concerning the development of drugs that modulate ARs. Through preclinical and clinical research, it has become evident that the modulation of ARs holds promise for the treatment of numerous diseases, including central nervous system disorders, cardiovascular and metabolic conditions, inflammatory and autoimmune diseases, and cancer. The latest studies discussed herein shed light on novel mechanisms through which ARs exert control over pathophysiological states. They also introduce new ligands and innovative strategies for receptor activation, presenting compelling evidence of efficacy along with the implicated signaling pathways. Collectively, these emerging insights underscore a promising trajectory toward harnessing the therapeutic potential of these multifaceted targets.

show abstract

Pathophysiology roles for adenosine 2A receptor in obesity and related diseases

Cited by 7 publications

References 139 publications

Association of non-alcoholic fatty liver disease with self-reported osteoarthritis among the US adults

Association of non-alcoholic fatty liver disease with self-reported osteoarthritis among the US adults

Role of the Sympathetic Nervous System in Mild Chronic Inflammatory Diseases: Focus on Osteoarthritis

Pharmacology of Adenosine Receptors: Recent Advancements

Contact Info

Product

Resources

About